Fortrea (NASDAQ:FTRE) Given New $16.00 Price Target at Robert W. Baird

Fortrea (NASDAQ:FTRE) had its target price lowered by Robert W. Baird from $19.00 to $16.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Truist Financial set a $22.00 target price on shares of Fortrea and gave the stock a “buy” rating in a research report on Thursday, January 8th. Evercore set a $25.00 price objective on Fortrea and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Mizuho set a $15.00 target price on Fortrea in a report on Friday, January 9th. Wedbush set a $21.00 price target on shares of Fortrea in a research report on Thursday, December 11th. Finally, Barclays set a $15.00 target price on shares of Fortrea and gave the company an “equal weight” rating in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $16.15.

Fortrea Stock Down 0.7%

FTRE stock opened at $10.72 on Friday. The stock has a market capitalization of $990.53 million, a P/E ratio of -0.98, a P/E/G ratio of 0.33 and a beta of 1.59. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.00 and a quick ratio of 1.00. Fortrea has a 1-year low of $3.97 and a 1-year high of $18.67. The business has a fifty day moving average price of $15.14 and a 200-day moving average price of $12.31.

Fortrea (NASDAQ:FTRE) last posted its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.07). Fortrea had a negative net margin of 36.21% and a positive return on equity of 5.97%. The company had revenue of $660.50 million for the quarter, compared to the consensus estimate of $665.22 million. Equities analysts forecast that Fortrea will post 0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP grew its holdings in Fortrea by 6,802.4% during the 2nd quarter. Allworth Financial LP now owns 5,660 shares of the company’s stock valued at $28,000 after buying an additional 5,578 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Fortrea by 214.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,341 shares of the company’s stock valued at $28,000 after acquiring an additional 2,278 shares in the last quarter. Larson Financial Group LLC increased its holdings in Fortrea by 136.7% in the 4th quarter. Larson Financial Group LLC now owns 1,856 shares of the company’s stock valued at $32,000 after acquiring an additional 1,072 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Fortrea by 74.3% in the 2nd quarter. Osaic Holdings Inc. now owns 6,844 shares of the company’s stock worth $38,000 after purchasing an additional 2,918 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Fortrea by 137.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,713 shares of the company’s stock valued at $43,000 after purchasing an additional 5,036 shares during the last quarter.

Key Stories Impacting Fortrea

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said full‑year revenue and adjusted EBITDA delivered in line with targets and that full‑year cost savings exceeded prior targets — a reassurance on operational execution. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
• Positive Sentiment: Robert W. Baird kept an “outperform” rating and a $16 price target (implying ~49% upside vs. current levels), signaling some analysts remain bullish on the company’s longer‑term outlook. Baird price target note
• Neutral Sentiment: Several full transcripts and earnings‑call highlights were published (useful for parsing management commentary and client/contract trends), giving investors primary‑source detail on drivers and margin dynamics. Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage remains active — a recent Benzinga roundup reviews seven ratings, which can amplify volatility as differing views are disseminated. Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
• Negative Sentiment: Q4 results missed consensus: reported EPS $0.09 vs. $0.16 expected, and revenue $660.5M vs. ~$665M expected — the headline misses are driving the immediate negative reaction. Fortrea Q4 Earnings and Revenues Lag Estimates (Zacks)
• Negative Sentiment: Barclays cut its price target to $12 and set an “equal weight” rating — a formal shift toward neutrality/less bullishness that can pressure sentiment and weaken near‑term buyer conviction. Barclays price target cut
• Negative Sentiment: FY‑2026 revenue guidance was given in a range (~$2.6B–$2.7B), which sits slightly below consensus at the top end — the cautious top‑line outlook and an unclear EPS guide left some investors wanting more upside visibility. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.